Abstract

P-element-induced wimpy testis (PIWI) proteins have been described in several cancers. PIWIL1 and PIWIL2 have been recently evaluated in pancreatic cancer, and elevated expression of PIWIL2 conferred longer survival to patients. However, PIWIL3’s and PIWIL4’s role in carcinogenesis is rather controversial, and their clinical implication in pancreatic cancer has not yet been investigated. In the present study, we evaluated PIWIL1, PIWIL2, PIWIL3 and PIWIL4 expression in pancreatic cancer-derived cell lines and in one non-tumor cell line as healthy control. Here, we show a differential expression in tumor and non-tumor cell lines of PIWIL3 and PIWIL4. Subsequently, functional experiments with PIWIL3 and/or PIWIL4 knockdown revealed a decrease in the motility ratio of tumor and non-tumor cell lines through downregulation of mesenchymal factors in pro of epithelial factors. We also observed that PIWIL3 and/or PIWIL4 silencing impaired undifferentiated phenotype and enhanced drug toxicity in both tumor- and non-tumor-derived cell lines. Finally, PIWIL3 and PIWIL4 evaluation in human pancreatic cancer samples showed that patients with low levels of PIWIL4 protein expression presented poor prognosis. Therefore, PIWIL3 and PIWIL4 proteins may play crucial roles to keep pancreatic cell homeostasis not only in tumors but also in healthy tissues.

Highlights

  • Pancreatic cancer (PC) has arisen as one of the tumors with higher incidence in developed countries

  • Since PIWIL3 and PIWIL4 expression has not been studied in PC and the functions of P-element-induced wimpy testis (PIWI) proteins in cancer seem to be rather controversial, we have evaluated the role of PIWIL3 and PIWIL4 expression in pancreatic cells and dissect their prognostic potential in PC

  • All human PIWI proteins were evaluated by Western blot and by immunohistochemistry (IHC) in a panel of five PC-derived cell lines: four from duct-adenocarcinoma differentiation (BxPC-3, Panc04.03, PL45 and RWP1), and one from epithelioid-carcinoma differentiation (PANC-1)

Read more

Summary

Introduction

Pancreatic cancer (PC) has arisen as one of the tumors with higher incidence in developed countries. The incidence of PC is expected to be higher than breast, prostate or colorectal cancers and to reach the second cause of cancer-related death by 2030 [1]. Adjuvant treatment for complete resected patients (R0) is usually based on Gemcitabine [4], or 5-fluorouracil for six months [5]. Regimens based on Gemcitabine in combination with Nanoalbumin bound-Paclitaxel (Nab-Paclitaxel) is recommended to patients with advanced disease [6]. PC develops multi-pathways chemoresistance as a result of the interaction between tumor cells, cancer stem cells and the tumor microenvironment [7]

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call